572 related articles for article (PubMed ID: 19961929)
41. CXCR4-targeted Nanoparticles Reduce Cell Viability, Induce Apoptosis and Inhibit SDF-1α Induced BT-549-Luc Cell Migration In Vitro.
Chittasupho C; Kewsuwan P; Murakami T
Curr Drug Deliv; 2017; 14(8):1060-1070. PubMed ID: 28215173
[TBL] [Abstract][Full Text] [Related]
42. Improved cytotoxicity and preserved level of cell death induced in colon cancer cells by doxorubicin after its conjugation with iron-oxide magnetic nanoparticles.
Augustin E; Czubek B; Nowicka AM; Kowalczyk A; Stojek Z; Mazerska Z
Toxicol In Vitro; 2016 Jun; 33():45-53. PubMed ID: 26911730
[TBL] [Abstract][Full Text] [Related]
43. Preparation and characterization of teniposide PLGA nanoparticles and their uptake in human glioblastoma U87MG cells.
Mo L; Hou L; Guo D; Xiao X; Mao P; Yang X
Int J Pharm; 2012 Oct; 436(1-2):815-24. PubMed ID: 22846410
[TBL] [Abstract][Full Text] [Related]
44. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells.
Tahara K; Kato Y; Yamamoto H; Kreuter J; Kawashima Y
J Microencapsul; 2011; 28(1):29-36. PubMed ID: 21171814
[TBL] [Abstract][Full Text] [Related]
45. Hyaluronic acid ion-pairing nanoparticles for targeted tumor therapy.
Li W; Yi X; Liu X; Zhang Z; Fu Y; Gong T
J Control Release; 2016 Mar; 225():170-82. PubMed ID: 26826304
[TBL] [Abstract][Full Text] [Related]
46. In vitro evaluation of doxorubicin-incorporated magnetic albumin nanospheres.
Zeybek A; Şanlı-Mohamed G; Ak G; Yılmaz H; Şanlıer ŞH
Chem Biol Drug Des; 2014 Jul; 84(1):108-15. PubMed ID: 24524300
[TBL] [Abstract][Full Text] [Related]
47. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
Liu SQ; Tong YW; Yang YY
Biomaterials; 2005 Aug; 26(24):5064-74. PubMed ID: 15769542
[TBL] [Abstract][Full Text] [Related]
48. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Aravind A; Jeyamohan P; Nair R; Veeranarayanan S; Nagaoka Y; Yoshida Y; Maekawa T; Kumar DS
Biotechnol Bioeng; 2012 Nov; 109(11):2920-31. PubMed ID: 22615073
[TBL] [Abstract][Full Text] [Related]
49. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance.
Liu Y; Pan J; Feng SS
Int J Pharm; 2010 Aug; 395(1-2):243-50. PubMed ID: 20472049
[TBL] [Abstract][Full Text] [Related]
50. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
51. Covalent attachment of Mn-porphyrin onto doxorubicin-loaded poly(lactic acid) nanoparticles for potential magnetic resonance imaging and pH-sensitive drug delivery.
Jing L; Liang X; Li X; Yang Y; Dai Z
Acta Biomater; 2013 Dec; 9(12):9434-41. PubMed ID: 23962645
[TBL] [Abstract][Full Text] [Related]
52. PEGylated and poloxamer-modified chitosan nanoparticles incorporating a lysine-based surfactant for pH-triggered doxorubicin release.
Scheeren LE; Nogueira DR; Macedo LB; Vinardell MP; Mitjans M; Infante MR; Rolim CM
Colloids Surf B Biointerfaces; 2016 Feb; 138():117-27. PubMed ID: 26674840
[TBL] [Abstract][Full Text] [Related]
53. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
[TBL] [Abstract][Full Text] [Related]
54. Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders.
Egusquiaguirre SP; Manguán-García C; Pintado-Berninches L; Iarriccio L; Carbajo D; Albericio F; Royo M; Pedraz JL; Hernández RM; Perona R; Igartua M
Eur J Pharm Biopharm; 2015 Apr; 91():91-102. PubMed ID: 25660910
[TBL] [Abstract][Full Text] [Related]
55. A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.
Kucuksayan E; Bozkurt F; Yilmaz MT; Sircan-Kucuksayan A; Hanikoglu A; Ozben T
Sci Rep; 2021 Jun; 11(1):13027. PubMed ID: 34158544
[TBL] [Abstract][Full Text] [Related]
56. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
Wang S; Zhang J; Wang Y; Chen M
Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
[TBL] [Abstract][Full Text] [Related]
57. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
Kong F; Tang C; Yin C
Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
[TBL] [Abstract][Full Text] [Related]
58. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
59. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
60. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy.
Lale SV; R G A; Aravind A; Kumar DS; Koul V
Biomacromolecules; 2014 May; 15(5):1737-52. PubMed ID: 24689987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
